https://www.selleckchem.com/pr....oducts/santacruzamat
In sTBI patients, plasma miR-9-3p levels were 6.5- and 9.2-fold in comparison to the mTBI and control groups, respectively. Thus, plasma miR-9-3p and miR-136-3p were identified as promising biomarker candidates for mTBI requiring further evaluation in a larger patient population.At present, the one-stage detector based on the lightweight model can achieve real-time speed, but the detection performance is challenging. To enhance the discriminability and robustness of the model extraction features and improve the detecto
Like
Comment
Share
